Green Alpha Advisors LLC Sells 446 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Green Alpha Advisors LLC trimmed its stake in Exact Sciences Co. (NASDAQ:EXASFree Report) by 11.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,618 shares of the medical research company’s stock after selling 446 shares during the period. Green Alpha Advisors LLC’s holdings in Exact Sciences were worth $203,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Groupama Asset Managment bought a new position in shares of Exact Sciences during the third quarter worth about $821,000. Sculptor Capital LP acquired a new stake in Exact Sciences during the 2nd quarter valued at approximately $32,819,000. Samlyn Capital LLC bought a new position in Exact Sciences during the 2nd quarter worth approximately $30,426,000. Armistice Capital LLC lifted its position in shares of Exact Sciences by 91.6% in the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock worth $59,154,000 after purchasing an additional 669,438 shares during the period. Finally, ArrowMark Colorado Holdings LLC bought a new stake in shares of Exact Sciences in the 3rd quarter valued at $28,608,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent analyst reports. Raymond James restated a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. Evercore ISI cut their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Citigroup lowered their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group cut their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Jefferies Financial Group lifted their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $72.94.

Get Our Latest Stock Analysis on EXAS

Exact Sciences Stock Up 3.6 %

Shares of NASDAQ:EXAS opened at $58.51 on Tuesday. The stock has a market cap of $10.83 billion, a price-to-earnings ratio of -50.01 and a beta of 1.24. The business’s 50 day moving average is $57.57 and its 200 day moving average is $58.98. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. The company’s revenue for the quarter was up 12.8% on a year-over-year basis. On average, sell-side analysts forecast that Exact Sciences Co. will post -1.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of Exact Sciences stock in a transaction dated Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.36% of the company’s stock.

Exact Sciences Company Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Further Reading

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.